Abstract

BackgroundIn the current study, we aimed to develop an algorithm based on biomarkers obtained through non- or minimally invasive procedures to identify healthy elderly subjects who have an increased risk of abnormal cerebrospinal fluid (CSF) amyloid beta42 (Aβ) levels consistent with the presence of Alzheimer’s disease (AD) pathology. The use of the algorithm may help to identify subjects with preclinical AD who are eligible for potential participation in trials with disease modifying compounds being developed for AD. Due to this pre-selection, fewer lumbar punctures will be needed, decreasing overall burden for study subjects and costs.MethodsHealthy elderly subjects (n = 200; age 65–70 (N = 100) and age > 70 (N = 100)) with an MMSE > 24 were recruited. An automated central nervous system test battery was used for cognitive profiling. CSF Aβ1-42 concentrations, plasma Aβ1-40, Aβ1-42, neurofilament light, and total Tau concentrations were measured. Aβ1-42/1-40 ratio was calculated for plasma. The neuroinflammation biomarker YKL-40 and APOE ε4 status were determined in plasma. Different mathematical models were evaluated on their sensitivity, specificity, and positive predictive value. A logistic regression algorithm described the data best. Data were analyzed using a 5-fold cross validation logistic regression classifier.ResultsTwo hundred healthy elderly subjects were enrolled in this study. Data of 154 subjects were used for the per protocol analysis. The average age of the 154 subjects was 72.1 (65–86) years. Twenty-four (27.3%) were Aβ positive for AD (age 65–83). The results of the logistic regression classifier showed that predictive features for Aβ positivity/negativity in CSF consist of sex, 7 CNS tests, and 1 plasma-based assay. The model achieved a sensitivity of 70.82% (± 4.35) and a specificity of 89.25% (± 4.35) with respect to identifying abnormal CSF in healthy elderly subjects. The receiver operating characteristic curve showed an AUC of 65% (± 0.10).ConclusionThis algorithm would allow for a 70% reduction of lumbar punctures needed to identify subjects with abnormal CSF Aβ levels consistent with AD. The use of this algorithm can be expected to lower overall subject burden and costs of identifying subjects with preclinical AD and therefore of total study costs.Trial registrationISRCTN.org identifier: ISRCTN79036545 (retrospectively registered).

Highlights

  • In the current study, we aimed to develop an algorithm based on biomarkers obtained through nonor minimally invasive procedures to identify healthy elderly subjects who have an increased risk of abnormal cerebrospinal fluid (CSF) amyloid beta42 (Aβ) levels consistent with the presence of Alzheimer’s disease (AD) pathology

  • We aimed to develop an algorithm based on minimally invasive biomarkers, to be used for pre-selection of subjects with an increased risk of lowered, abnormal, CSF Amyloid beta (Aβ) levels (“Aβ positive subjects”) consistent with the presence of AD pathology

  • Demographic and clinical characteristics Two hundred healthy elderly subjects were enrolled in this study of which 189 were included in the CSF and plasma analyses due to CSF availability

Read more

Summary

Introduction

We aimed to develop an algorithm based on biomarkers obtained through nonor minimally invasive procedures to identify healthy elderly subjects who have an increased risk of abnormal cerebrospinal fluid (CSF) amyloid beta (Aβ) levels consistent with the presence of Alzheimer’s disease (AD) pathology. Further analyses showed that in one of the two phase 3 trials the patient group that received the highest dose of the active compound showed slower cognitive decline than the placebo group [5] Based on these results, the FDA recently approved aducanumab for the treatment of AD in the USA under the “accelerated approval pathway” which provides patients access to drugs when there is an expectation of clinical benefit despite some uncertainty about the clinical benefit of the drug [6]. Many phase 3 anti-amyloid trials have failed to demonstrate effects on progression of cognitive decline in patients with (mild to moderate) AD, despite clear Aβ lowering effects in cerebrospinal fluid (CSF) or PET [8,9,10,11,12]

Objectives
Methods
Results
Discussion
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.